Karen Harris

Karen Harris is a professional writer and editor with more than two decades of experience in research-driven nonfiction writing. With a background in journalism and a Master's degree in English, she brings a meticulous approach to fact-finding, source evaluation, and clear communication of complex topics. Her work spans health, lifestyle, and consumer education, always with a focus on accuracy and readability.

Context

Conventional infant formulas have historically contained higher iron and protein levels than human milk, partly as a safety buffer. A growing body of evidence suggests that lower concentrations - closer to human milk - may be sufficient. This trial tested whether adding a bovine MFGM ingredient while simultaneously reducing iron, protein, and ARA concentrations supports adequate growth and iron status through the first year of life.

Study Overview

Design: Multicenter, double-blind, randomized, controlled, parallel-group trial


Population: 373 healthy term infants (≥37 weeks, ≥2,500 g birth weight), enrolled at 10–14 days of age across 22 US sites


Follow-up: Day 14 to Day 365; exclusive study formula feeding through Day 120


Funding: Fully industry-funded (Reckitt/Mead Johnson Nutrition); multiple authors are Reckitt/MJN employees


Evidence Certainty (GRADE): Not formally assessed; single industry-funded trial


Comparison:

  • Control formula: Marketed Enfamil® - protein 2.1 g/100 kcal, iron 1.8 mg/100 kcal, ARA 34 mg/100 kcal, no added MFGM
  • INV-MFGM formula: Protein 1.9 g/100 kcal, iron 1.2 mg/100 kcal, ARA 25 mg/100 kcal + whey protein-lipid concentrate 5 g/L (source of bovine MFGM, Lacprodan® MFGM-10, Arla Foods)

Key Findings

Primary outcome - Growth:

  • No statistically significant difference in weight gain rate (g/day) from Day 14–120 in either males or females (primary endpoint met)
  • No significant group differences in weight, length, or head circumference growth rates at any measured interval through Day 365
  • Exception: Mean achieved weight in female infants at Day 365 was statistically lower in the MFGM group (9,468 g vs. 9,892 g; p=0.034) - clinical significance unclear
  • Both groups tracked within normal WHO growth percentiles throughout

Secondary outcome - Iron status (Day 365):

  • No significant group differences in hemoglobin or hematocrit; the majority of infants in both groups fell within laboratory reference ranges (Hb: control 88%, MFGM 91%)
  • Serum ferritin was significantly higher in the control group (median 50.0 vs. 42.0 μg/L; p=0.048), consistent with higher dietary iron intake - but both groups were predominantly within reference ranges
  • No significant group difference in clinical anemia incidence (control 3%, MFGM 1%)

Tolerance:

  • No significant group differences in fussiness, gassiness, or stool frequency at any time point
  • One significant stool consistency difference at Day 90 only (more unformed/seedy stools in MFGM group; p=0.004); not sustained at other time points
  • Medically confirmed gas was lower in the MFGM group (5% vs. 13%; p=0.010)
  • No significant group differences in eczema, serious adverse events, or formula discontinuation rates

Limitations

  • The investigational formula differed from the control in four variables simultaneously (MFGM, iron, protein, ARA) - it is impossible to attribute any outcome specifically to MFGM
  • No human milk reference group included
  • Complementary feeding after Day 120 was not systematically tracked, limiting dietary interpretation of iron status data at Day 365
  • Fully industry-funded; majority of authors are employees of the sponsor (Reckitt/MJN)
  • Single trial; not independently replicated
  • The statistically lower achieved weight in girls at Day 365 is unexplained and warrants attention in future studies
  • Powered solely for the primary growth endpoint; secondary outcomes (including iron status) are hypothesis-generating

Neutral Interpretation

This trial demonstrates that an infant formula containing added bovine MFGM alongside reduced iron (1.2 mg/100 kcal), protein (1.9 g/100 kcal), and ARA was well-tolerated and associated with growth within normal WHO ranges through 12 months, with no clinically meaningful difference in iron status compared to a standard marketed formula. However, because the investigational and control formulas differed in four nutritional variables at once, no conclusions can be drawn about the specific contribution of MFGM. The study was fully industry-funded by the formula manufacturer, which limits independence of interpretation.

Full Citation

Hedrick J, Yeiser M, Harris CL, Wampler JL, London HE, Patterson AC, Wu SS. Infant Formula with Added Bovine Milk Fat Globule Membrane and Modified Iron Supports Growth and Normal Iron Status at One Year of Age: A Randomized Controlled Trial. Nutrients. 2021;13(12):4541. doi: 10.3390/nu13124541. 

PMID: 34960093. 

Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8708584/

Disclosure

This summary is based on the published study. It is provided for informational purposes only and does not constitute medical advice. Funding source and conflicts of interest are disclosed as reported by the authors.